HENGRUI PHARMA (01276.HK): Five Innovative Drugs Obtain Clinical Trial Approvals, Targeting KRAS G12D and Other Indications

NewTimeSpace News: Jiangsu Hengrui Pharmaceutical Co., Ltd. (01276.HK) released an overseas regulatory announcement on May 8, 2026. The Company and its subsidiaries have received Notices of Approval for Clinical Trials from the National Medical Products Administration (NMPA) for HRS-6093 Tablets, SHR-9839 (sc) for Injection, SHR-1826 for Injection, Adebrelimab Injection, and SHR-8068 Injection.
The NMPA has approved joint clinical trials of these products for the treatment of advanced malignant solid tumors with KRAS G12D mutation.
Details of each product:
HRS-6093 Tablets
A novel, potent, and selective oral KRAS G12D inhibitor that binds specifically to the KRAS G12D mutant protein to exert anti-tumor effects. No similar products have been approved for marketing worldwide.Accumulated R&D investment: ~RMB 53.3 million.
SHR-9839 (sc) for Injection
A subcutaneous formulation of SHR-9839, a self-developed humanized antibody drug. It blocks two key signaling pathways involved in tumorigenesis and progression.Accumulated R&D investment: ~RMB 109.5 million.
SHR-1826 for Injection
A c-Met–targeted antibody-drug conjugate (ADC). A similar product, ABBV-399, was granted accelerated approval by the U.S. FDA in May 2025.Accumulated R&D investment: ~RMB 140.9 million.
Adebrelimab Injection
A self-developed humanized anti-PD-L1 monoclonal antibody, approved in 2023. Global sales of same-target products reached approximately USD 9.648 billion in 2024.Accumulated R&D investment: ~RMB 1.1747 billion.
SHR-8068 Injection
A fully human anti-CTLA-4 monoclonal antibody licensed by the Company. Global sales of two similar products totaled approximately USD 1.68 billion in 2025.Accumulated R&D investment: ~RMB 368.1 million.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.